You are here

Our science / Clinical Trials / Find a Trial / NCT00334750

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Back to Search Print Save as PDF Bookmark Trial

NCT00334750

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Calgary, Alberta, T3E 7M8 Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Open-Angle Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects diagnosed at study visit or within 3 months of visit with OH

- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- No prior treatment for OH or OAG

- No prior ocular surgery or history of ocular trauma

NCT00334750
Pfizer
Completed
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
NCT02060487
All Genders
18+
Years
Multiple Sites
Impotence, Hypertension
To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .
NCT00150358
Males
18+
Years
Multiple Sites
Familial Persistent Pulmonary Hypertension
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
NCT01720524
All Genders
0+
Years
Multiple Sites
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
NCT01379144
All Genders
18+
Years
Multiple Sites
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Canadian population
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Other: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Intervention: Other: There is no intervention in this study.
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
410
April 2009
April 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects diagnosed at study visit or within 3 months of visit with OH
  • OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

  • No prior treatment for OH or OAG
  • No prior ocular surgery or history of ocular trauma
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00334750
A6111125
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now